Global Leading Market Research Publisher QYResearch announces the release of its latest report “Night Blindness Treatment – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″.
Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart):
https://www.qyresearch.com/reports/3670440/night-blindness-treatment
To Ophthalmology Drug Executives, Healthcare Portfolio Managers, and Pharmaceutical Investors:
If your organization develops or markets treatments for retinal disorders or vitamin deficiencies, you may be aware of a specific but underserved ophthalmic condition: night blindness (nyctalopia)—a disorder in which the eyes are unable to adjust to low light conditions, affecting a person’s ability to see in dimly lit areas or at night. Night blindness is most commonly caused by abnormalities with rod cells (the photoreceptors responsible for scotopic vision), but it can also result from vitamin A deficiency, retinitis pigmentosa, other inherited retinal dystrophies, cataracts, or certain drug toxicities. The treatment for night blindness is entirely dependent on the underlying cause. According to QYResearch’s newly released market forecast, the global night blindness treatment market was valued at US$15.6 million in 2024 and is projected to reach US$19.9 million by 2031, growing at a compound annual growth rate (CAGR) of 3.6 percent during the 2025-2031 forecast period. This niche but steady market reflects the ongoing need for vitamin A-based therapies for nutritional deficiency-related night blindness, as well as supportive treatments for inherited retinal disorders.
1. Product Definition: Treating the Underlying Cause of Nyctalopia
Night blindness, also termed nyctalopia, is a disorder in which your eyes are unable to adjust to low light circumstances. The condition is characterized by difficulty seeing in dimly lit areas or at night, with symptoms including eye pain, vomiting, cloudy vision, halos around lights, light sensitivity (photophobia), distance vision problems, and headache—though symptoms vary depending on the underlying cause.
The primary causes of night blindness include: vitamin A deficiency (the most common cause globally, particularly in developing countries where malnutrition is prevalent; vitamin A is essential for the production of rhodopsin, the light-absorbing pigment in rod cells), retinitis pigmentosa (a group of inherited retinal dystrophies characterized by progressive rod and cone degeneration), other inherited retinal disorders (including congenital stationary night blindness, fundus albipunctatus, and Oguchi disease), cataracts (clouding of the lens that scatters light, reducing contrast sensitivity in low light), high myopia (severe nearsightedness associated with retinal degeneration), and certain drug toxicities (including hydroxychloroquine, chloroquine, and some antipsychotic medications).
The treatment for night blindness is entirely dependent on the underlying reason. For vitamin A deficiency-related night blindness, treatment involves vitamin A supplementation (oral vitamin A, typically 10,000-25,000 IU daily or weekly dosing depending on deficiency severity). For retinitis pigmentosa and other inherited retinal disorders, there is no cure, but treatments may include vitamin A supplementation (some studies suggest that 15,000 IU/day of vitamin A palmitate may slow progression), gene therapy (Luxturna for RPE65-mediated retinal dystrophy), retinal implants (Argus II, though now discontinued), and low vision aids and supportive care. For cataract-related night blindness, treatment is cataract surgery (lens replacement). For drug-induced night blindness, treatment is discontinuation of the causative medication (if medically appropriate).
The market is segmented by product type into Vitamin AD Drops (ophthalmic formulations combining vitamin A and vitamin D for local ocular application), Vitamin AD Softgels (oral softgel capsules containing vitamins A and D), and Vitamin A Capsules (oral vitamin A supplementation, typically as retinyl palmitate or retinyl acetate). Vitamin A Capsules currently represent the largest segment (approximately 50-55 percent of revenue), as oral vitamin A supplementation is the primary treatment for nutritional deficiency-related night blindness, which represents the majority of cases globally.
By application, the market serves clinics (outpatient ophthalmology clinics, primary care clinics, nutrition clinics) and hospitals (hospital pharmacies, ophthalmology departments, pediatric departments for vitamin A deficiency treatment). Hospitals currently represent the larger segment (approximately 60-65 percent of revenue), particularly in developing countries where vitamin A deficiency is more prevalent and treatment is provided through public health programs. Clinics are the faster-growing segment (approximately 4-5 percent CAGR) in developed countries as vitamin A supplementation for retinitis pigmentosa is managed by ophthalmology specialists.
2. Broader Pharmaceutical Market Context
The global pharmaceutical market is substantial and growing. According to industry data, the global pharmaceutical market was valued at US$1,475 billion in 2022, growing at a CAGR of approximately 5 percent during the following six years. The pharmaceutical market includes chemical drugs (traditional small-molecule drugs) and biological drugs (biologics, including gene therapies, monoclonal antibodies, recombinant proteins). For biologics, the market was estimated at US$381 billion in 2022. In comparison, the chemical drug market was estimated to increase from US$1,005 billion in 2018 to US$1,094 billion in 2022.
The pharmaceutical market is driven by several positive factors: increasing demand for healthcare (aging populations, expanding access to care in developing countries), technological advancements (precision medicine, gene therapy, RNA therapeutics, cell therapy), and the rising prevalence of chronic diseases (diabetes, cardiovascular disease, cancer, neurodegenerative disorders). Additionally, increased funding from private and government organizations for the development of pharmaceutical manufacturing segments and rise in research and development activities for drugs are accelerating innovation.
However, the pharmaceutical industry also faces significant challenges: stringent regulatory requirements (FDA, EMA, NMPA, PMDA approval processes), high costs of research and development (average cost to develop a new drug exceeds US$1-2 billion), and patent expirations (loss of exclusivity for blockbuster drugs, leading to generic competition and revenue decline). Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need.
The COVID-19 pandemic highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs. The rapid development and deployment of mRNA vaccines (Pfizer-BioNTech, Moderna) demonstrated that accelerated development timelines are possible with sufficient investment, collaboration, and regulatory flexibility.
3. Night Blindness Treatment Market Dynamics
Within the broader ophthalmic pharmaceutical market, the night blindness treatment segment is small (US$15.6 million in 2024) but stable, with a projected CAGR of 3.6 percent through 2031. This niche market size reflects several factors.
First, vitamin A deficiency-related night blindness is primarily a public health issue in developing countries (sub-Saharan Africa, South Asia, Southeast Asia). Treatment is typically provided through government public health programs (mass vitamin A supplementation campaigns) or by non-governmental organizations (WHO, UNICEF), often at low cost (vitamin A capsules cost pennies per dose). Commercial pharmaceutical sales for this indication are therefore limited, as the market is dominated by non-profit and public sector procurement.
Second, inherited retinal disorders causing night blindness (retinitis pigmentosa, congenital stationary night blindness) are rare diseases. The prevalence of retinitis pigmentosa is approximately 1 in 4,000 people globally, representing a total addressable patient population of approximately 2 million people worldwide. While this represents a larger commercial opportunity than vitamin A deficiency in developed countries, treatment options remain limited. Luxturna (voretigene neparvovec), a gene therapy for RPE65-mediated retinal dystrophy, costs approximately US$850,000 per patient and is not widely available. Vitamin A supplementation for retinitis pigmentosa (15,000 IU/day) is off-label in many countries, supported by limited clinical evidence (the Berson study, 1993), and is not aggressively marketed by pharmaceutical companies.
Third, other causes of night blindness (cataracts, high myopia, drug toxicity) are treated by addressing the underlying condition (surgery, refractive correction, medication discontinuation) rather than through specific night blindness drugs, and therefore do not contribute significantly to the pharmaceutical market for night blindness treatment.
Exclusive Analyst Observation (Q2 2025 Data): The night blindness treatment market is unusual in that the dominant therapy—vitamin A supplementation—is an off-patent, low-cost generic product. Major pharmaceutical companies (Merck, Pfizer, Roche, Novartis, Bayer) are listed as market participants, but their revenue from this indication is minimal. These companies likely include vitamin A products in their broader vitamin/supplement portfolios or generic drug divisions, but night blindness treatment is not a strategic focus. For investors, the night blindness treatment market represents a low-growth, low-margin commodity pharmaceutical segment, not a high-growth therapeutic area. The more interesting opportunities in retinal disorders are in gene therapies for inherited retinal dystrophies (Luxturna from Spark Therapeutics/Roche, other gene therapies in development) and neuroprotective agents for retinitis pigmentosa (currently in clinical trials).
4. Competitive Landscape: Major Pharmaceutical Companies
Based on QYResearch 2024-2025 market data and confirmed by company annual reports, the night blindness treatment market includes virtually all major global pharmaceutical companies, primarily through their vitamin product lines or generic drug divisions. Key players include Merck (Germany, vitamin and supplement portfolio), Pfizer (US, generics division), GlaxoSmithKline (UK, consumer health and vitamin products), Johnson & Johnson Private Limited, Roche Holding AG (Switzerland, also owner of Spark Therapeutics with Luxturna gene therapy for inherited retinal dystrophy), Abbott (US, nutrition and vitamin products), Mylan (US, now part of Viatris, generic drugs), Teva Pharmaceuticals (Israel, generics), Sanofi (France, generics and consumer health), Novartis (Switzerland, generics division Sandoz), Bayer (Germany, consumer health and vitamins), Sun Pharmaceutical Industries (India, generics), Aurobindo Pharma (India, generics), Lupin Pharma (India, generics), Eli Lilly (US), Sumitomo Dainippon Pharma (Japan), Leo Pharma (Denmark), Bausch Health (Canada, formerly Valeant), AstraZeneca (UK/Sweden), and Cipla (India, generics).
5. Market Outlook 2025-2031 and Strategic Recommendations
Based on QYResearch forecast models, the global night blindness treatment market will reach US$19.9 million by 2031 at a CAGR of 3.6 percent.
For pharmaceutical executives: Night blindness treatment is a low-priority indication for major pharmaceutical companies, as the market is small and dominated by low-cost generic vitamin A products. However, for companies with existing vitamin/supplement portfolios, this represents a stable, low-growth revenue stream with minimal investment required.
For marketing managers: Position vitamin A products not as “night blindness treatments” but as essential nutritional supplements for populations at risk of deficiency (pregnant women, children in developing countries, individuals with malabsorption disorders). Night blindness is one of several deficiency symptoms.
For investors: The night blindness treatment market does not offer attractive growth or margin potential. Instead, focus on gene therapies and neuroprotective agents for inherited retinal disorders, which represent a larger, higher-growth, higher-margin opportunity within the broader retinal therapeutics space.
Key risks to monitor include continued global progress in reducing vitamin A deficiency through public health programs (which could reduce demand), competition from food fortification programs (golden rice, fortified cooking oil, fortified flour), and the potential for new gene therapies to address inherited retinal disorders causing night blindness.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
